> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 users with continuous glucose monitoring were more likely to stay on the drug
- URL: https://www.coios.me/glp-1-users-with-continuous-glucose-monitoring-were-more/
- Published: 2026-09-21T08:39:00.000Z
- Updated: 2026-09-21T08:41:09.000Z
- Description: In US claims data on 4,681 adults with type 2 diabetes starting a GLP-1 receptor agonist, 68.4% of adherent continuous glucose monitor users were still on the drug at 12 months against 51.9% of matched non-users (adjusted hazard ratio for stopping 0.56).
- Author: Daniel Ryan
- Tags: Healthcare today, Obesity, diabetes and the GLP-1 drugs, United States, #peer-reviewed, #new, #item, #source-2026-09

A matched cohort from US administrative claims for 2017 to 2024 compared GLP-1 receptor agonist discontinuation between 934 adults with type 2 diabetes using continuous glucose monitoring adherently and 3,747 matched non-users on non-intensive therapy. At one year 68.4% of monitor users remained on the drug against 51.9% of non-users, an adjusted hazard ratio for discontinuation of 0.56 (95% CI 0.49-0.63). Matching covered age, sex, ethnicity, therapy, comorbidity and insurance but not motivation or glycaemic control, which could account for part of the difference.

*Why it is interesting: Persistence rather than initiation decides whether GLP-1 drugs have any population-scale effect, and about half of the non-users here had stopped within a year.*

Source

[Diabetes Technology & Therapeutics, 19 September 2026](https://doi.org/10.1177/15209156261489904?ref=coios.me)

DOI

10.1177/15209156261489904

Type

Peer-reviewed article

Design

Retrospective matched-cohort study of US administrative claims (Inovalon Insights), 934 adherent CGM users matched to 3,747 non-users with type 2 diabetes starting a GLP-1 receptor agonist, 2017-2024

Verdict

New finding

Driver

[Obesity, diabetes and the GLP-1 drugs](https://www.coios.me/d-obesity-diabetes/)